CLRB on Nasdaq

Cellectar Biosciences, Inc.

American pharmaceutical preparations company based in Florham Park.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerCLRB on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersMadison, United States
Incorporated inDE²
Business address100 Campus Drive, Florham Park, Nj 07932²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷⁸-$23.0M in 2025+62% since 2019

Net income³⁴⁵⁶⁷⁸-$21.8M in 2025+55% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development	$11.5M	$26.1M
General and administrative	$11.5M	$25.6M
Total operating expenses	$23.0M	$51.8M
LOSS FROM OPERATIONS	-$23.0M	-$51.8M
Warrant issuance expense		-$7.7M
Gain on valuation of warrants	$753.7K	$13.8M
Interest income	$435.1K	$1.2M
Total other income (expense), net	$1.2M	$7.3M
LOSS BEFORE INCOME TAXES	-$21.8M	-$44.5M
INCOME TAX PROVISION (BENEFIT)		$66.0K
NET LOSS	-$21.8M	-$44.6M
NET LOSS PER SHARE - BASIC (In dollars per share)	-$8.35	-$36.52
NET LOSS PER SHARE - DILUTED (In dollars per share)	-$8.35	-$41.89
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC (In shares)	2.6M shares	1.2M shares
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED (In shares)	2.6M shares	1.2M shares

Total assets³⁴⁵⁶⁷⁸$15.0M in 2025+22% since 2019

Total liabilities³⁴⁵⁶⁷⁸$5.1M in 2025+59% since 2019

Shareholders’ equity⁴⁵⁶⁷⁸$8.5M in 2025−6% since 2019

Cash³⁴⁵⁶⁷⁸$13.2M in 2025+24% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$13.2M	$23.3M
Prepaid expenses and other current assets	$842.4K	$961.7K
Total current assets	$14.0M	$24.3M
Property, plant & equipment, net	$549.4K	$757.1K
Operating lease right-of-use asset	$360.7K	$436.9K
Other long-term assets	$29.8K	$29.8K
TOTAL ASSETS	$15.0M	$25.5M
Accounts payable and accrued liabilities	$4.4M	$7.6M
Warrant liability	$226.0K	$1.7M
Lease liability, current	$100.2K	$84.4K
Total current liabilities	$4.7M	$9.4M
Lease liability, net of current portion	$309.4K	$409.6K
TOTAL LIABILITIES	$5.1M	$9.8M
Common stock, $0.00001 par value; 170,000,000 shares authorized; 4,240,129 and 1,535,996 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$42	$15
Additional paid-in capital	$277.1M	$261.1M
Accumulated deficit	-$269.1M	-$247.3M
Total stockholders' equity	$8.5M	$14.3M	-$15.2M
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$15.0M	$25.5M
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	170.0M shares	170.0M shares
Common stock, shares issued	4.2M shares	1.5M shares
Common stock, shares outstanding	4.2M shares	1.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$13.2M	$23.3M
Prepaid expenses and other current assets	$842.4K	$961.7K
Total current assets	$14.0M	$24.3M
Property, plant & equipment, net	$549.4K	$757.1K
Operating lease right-of-use asset	$360.7K	$436.9K
Other long-term assets	$29.8K	$29.8K
TOTAL ASSETS	$15.0M	$25.5M
Accounts payable and accrued liabilities	$4.4M	$7.6M
Warrant liability	$226.0K	$1.7M
Lease liability, current	$100.2K	$84.4K
Total current liabilities	$4.7M	$9.4M
Lease liability, net of current portion	$309.4K	$409.6K
TOTAL LIABILITIES	$5.1M	$9.8M
Common stock, $0.00001 par value; 170,000,000 shares authorized; 4,240,129 and 1,535,996 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$42	$15
Additional paid-in capital	$277.1M	$261.1M
Accumulated deficit	-$269.1M	-$247.3M
Total stockholders' equity	$8.5M	$14.3M	-$15.2M
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$15.0M	$25.5M
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	170.0M shares	170.0M shares
Common stock, shares issued	4.2M shares	1.5M shares
Common stock, shares outstanding	4.2M shares	1.5M shares

Cash from operations³⁴⁵⁶⁷⁸-$23.1M in 2025+98% since 2019

Capital spending³⁴⁵⁶⁷⁸$5.9K in 2025−76% since 2019

Free cash flow³⁴⁵⁶⁷⁸-$23.1M in 2025+97% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$21.8M	-$44.6M
Depreciation and amortization	$213.6K	$291.7K
Stock-based compensation	$2.3M	$4.3M
Loss on disposal of assets		$145.7K
Warrant issuance expense		$7.7M
Change in fair value of warrants	-$753.7K	-$13.8M
Change in operating lease right-of-use asset	$76.2K	$65.4K
Prepaid expenses and other assets	$119.2K	-$73.4K
Accounts payable and accrued liabilities	-$3.2M	-$1.6M
Lease liability	-$84.4K	-$59.0K
Cash used in operating activities	-$23.1M	-$47.6M
Purchases of property, plant & equipment	-$5.9K	-$104.2K
Cash used in investing activities	-$5.9K	-$104.2K
Proceeds from exercise of warrants and new warrants, net of issuance costs	$7.2M	$61.4M
Proceeds from issuance of common stock, pre-funded warrants and common warrants, net of issuance costs	$5.8M
Cash provided by financing activities	$13.0M	$61.4M
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-$10.1M	$13.7M
Conversion of preferred stock to common stock		$67.6M
Settlement of warrants to equity	$738.3K	$12.6M

Compare Cellectar Biosciences, Inc. with another company

Leadership

Who has led Cellectar Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Jarrod Longcor2023–now

201520202025

Chief executive officerJames Caruso V. Aug 4, 2015 to now¹¹
Chief executive officerSimon Pedder Aug 18, 2014 to Aug 22, 2014¹²
PresidentJames Caruso V. Aug 4, 2015 to now¹¹
PresidentSimon Pedder Aug 18, 2014 to Aug 22, 2014¹²
Chief financial officerCharles Thomas Bernhardt Iii. Mar 11, 2019 to Mar 11, 2019¹³
Chief financial officerDov Elefant Sep 11, 2019 to Jan 27, 2022¹⁴
Chief financial officerBrian M. Posner Apr 5, 2018 to Jan 18, 2019¹⁵
Chief financial officerChad J. Kolean Aug 18, 2014 to Apr 5, 2018¹⁶
Chief operating officerJarrod Longcor Jan 18, 2023 to now¹⁷

Board members and other officers (21)

Senior Vice President, MedicalAndrei Shustov Mar 16, 2023 to Jun 18, 2024¹⁸
Chief Commercial OfficerDarrell Shane Lea Dec 15, 2022 to Jun 18, 2024¹⁹
Chief Medical OfficerIgor D. Grachev Jan 8, 2020 to Jan 8, 2020²⁰
VP, Chief Medical OfficerJohn E. Friend Ii. Apr 18, 2017 to Mar 5, 2021²¹
Sr. VP of Corp Dev & OpsJarrod Longcor Aug 12, 2016 to Jan 27, 2022²²
Chief Scientific OfficerJamey P. Weichert Aug 18, 2014 to May 23, 2016²³
VP of Business DevelopmentJohn Patrick Genn Aug 18, 2014 to Mar 4, 2015²⁴
OfficerKathryn M. McNeil Aug 18, 2014 to Aug 18, 2014²⁵
VP of Clinical DevelopmentCameron Szakacs Dec 18, 2014 to Dec 18, 2014²⁶
Board memberAndrew Gu Jun 9, 2026 to now²⁷
Board memberAsher Chanan-Khan Jul 2, 2021 to now²⁸
Board memberDouglas J. Swirsky Apr 18, 2017 to now²⁹
Board memberFrederick W. Driscoll Apr 18, 2017 to now³⁰
Board memberJames Caruso V. Aug 4, 2015 to now¹¹
Board memberStefan Loren Aug 5, 2015 to now³¹
Board memberJamey P. Weichert Aug 18, 2014 to Aug 18, 2014²³
Board memberJohn Neis Aug 18, 2014 to now³²
Board memberPaul L. Berns Aug 18, 2014 to Apr 21, 2016³³
Board memberSimon Pedder Aug 18, 2014 to Aug 22, 2014¹²
Board memberStephen A. Hill Aug 18, 2014 to Jun 25, 2020³⁴
Board memberBihua Chen Sep 5, 2014 to Sep 5, 2014³⁵

Former names

NOVELOS THERAPEUTICS, INC.Feb 28, 2005 to Feb 11, 2014²
COMMON HORIZONS INCJun 4, 2004 to Jun 2, 2005²

Timeline

Aug 4, 2015New chief executive James Caruso V. becomes CEO¹¹
Aug 18, 2014New chief executive Simon Pedder becomes CEO¹²
Jun 24, 1996Founded Cellectar Biosciences, Inc. is founded³⁶

Filings

269 filings to the SEC since October 2021: 9 annual reports, 16 quarterly reports, 72 major events, 64 insider forms, 43 large holders, 1 private raises, 64 other. The latest 20:

Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 13, 2026SCHEDULE 13G EDGAR
Aug 13, 20268-K EDGAR
Aug 13, 202610-Q EDGAR
Aug 4, 2026SCHEDULE 13G EDGAR
Jul 10, 20264/A OWNERSHIP DOCUMENT EDGAR
Jul 10, 20268-K EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jul 8, 20264 OWNERSHIP DOCUMENT EDGAR
Jun 9, 20263 OWNERSHIP DOCUMENT EDGAR

The 269 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 43 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Sep 8, 2023Raised $24.5 million in a private offering of equity Form D: 21 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Caligan Partners LP	469,998	$1.3M	0.1%	New
Nantahala Capital Management, LLC	439,996	$1.2M	0.0%	New
Stempoint Capital LP	354,938	$986.7K	0.2%	New
Vanguard Capital Management LLC	327,367	$910.1K	0.0%	+245,483
Silverarc Capital Management, LLC	321,728	$894.4K	0.1%	New
Bleichroeder LP	288,679	$802.5K	0.1%	+188,679
Jupiter Topco LLC	274,156	$759.4K	0.0%	New
Balyasny Asset Management L.P.	220,000	$611.6K	0.0%	New
Empery Asset Management, LP	189,605	$527.1K	0.6%	New
Diadema Partners LP	138,341	$384.6K	0.1%	New
Stonepine Capital Management, LLC	104,550	$290.6K	0.2%	New
Persistent Asset Partners Ltd	92,983	$258.5K	0.1%	New
Boothbay Fund Management, LLC	85,069	$236.5K	0.0%	New
Geode Capital Management, LLC	53,351	$148.3K	0.0%	+573
Vanguard Fiduciary Trust Co	46,220	$128.5K	0.0%	+29,647
Sequoia Financial Advisors, LLC	21,850	$60.7K	0.0%	+3,000
Riverview Capital Advisers, LLC	10,384	$50.1K	0.0%	No change
Northern Trust Corp	14,839	$41.3K	0.0%	New
BlackRock, Inc.	4,735	$13.2K	0.0%	−10
UBS Group AG	3,093	$8.6K	0.0%	−6,554
Barclays PLC	561	$1.6K	0.0%	New
Morgan Stanley	510	$1.4K	0.0%	No change
TD Waterhouse Canada Inc.	63	$178	0.0%	No change
Acadian Asset Management LLC	16,577	$46	0.0%	New
SBI Securities Co., Ltd.	11	$31	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCellectar Biosciences, Inc. filings on SEC EDGAR
2
SEC EDGARCellectar Biosciences, Inc. filings on SEC EDGAR
3
SEC EDGARCellectar Biosciences, Inc. 10-K for fiscal 2019
4
SEC EDGARCellectar Biosciences, Inc. 10-K for fiscal 2020
5
SEC EDGARCellectar Biosciences, Inc. 10-K for fiscal 2021
6
SEC EDGARCellectar Biosciences, Inc. 10-K for fiscal 2022
7
SEC EDGARCellectar Biosciences, Inc. 10-K for fiscal 2023
8
SEC EDGARCellectar Biosciences, Inc. 10-K for fiscal 2024
9
SEC EDGARCellectar Biosciences, Inc. 10-Q for fiscal 2026
10
SEC EDGARCellectar Biosciences, Inc. 10-Q for fiscal 2026
11
SEC EDGARJames Caruso V., Chief executive officer
12
SEC EDGARSimon Pedder, Chief executive officer
13
SEC EDGARCharles Thomas Bernhardt Iii., Chief financial officer
14
SEC EDGARDov Elefant, Chief financial officer
15
SEC EDGARBrian M. Posner, Chief financial officer
16
SEC EDGARChad J. Kolean, Chief financial officer
17
SEC EDGARJarrod Longcor, Chief operating officer
18
SEC EDGARAndrei Shustov, Senior Vice President, Medical
19
SEC EDGARDarrell Shane Lea, Chief Commercial Officer
20
SEC EDGARIgor D. Grachev, Chief Medical Officer
21
SEC EDGARJohn E. Friend Ii., VP, Chief Medical Officer
22
SEC EDGARJarrod Longcor, Sr. VP of Corp Dev & Ops
23
SEC EDGARJamey P. Weichert, Chief Scientific Officer
24
SEC EDGARJohn Patrick Genn, VP of Business Development
25
SEC EDGARKathryn M. McNeil, Officer
26
SEC EDGARCameron Szakacs, VP of Clinical Development
27
SEC EDGARAndrew Gu, Board member
28
SEC EDGARAsher Chanan-Khan, Board member
29
SEC EDGARDouglas J. Swirsky, Board member
30
SEC EDGARFrederick W. Driscoll, Board member
31
SEC EDGARStefan Loren, Board member
32
SEC EDGARJohn Neis, Board member
33
SEC EDGARPaul L. Berns, Board member
34
SEC EDGARStephen A. Hill, Board member
35
SEC EDGARBihua Chen, Board member
36
gleifCellectar Biosciences, Inc. is founded